- Evotec and Novo Nordisk have entered a collaboration to develop next-generation cell therapy technologies.
- The partnership will involve research and development at Evotec’s sites in Göttingen, Germany, and Modena, Italy.
Evotec has announced a strategic partnership with Novo Nordisk to advance the development of stem cell-based therapies. The collaboration focuses on creating next-generation off-the-shelf cell therapy products for clinical use, with the potential for commercialisation in the future.
The agreement will see Novo Nordisk provide funding for technology development at Evotec’s research and development site in Göttingen, Germany, as well as its certified cell therapy manufacturing facility in Modena, Italy. As part of the deal, Novo Nordisk will have the option to secure exclusive rights to use the results of the partnership in a specific therapeutic area. Evotec is set to receive research funding, alongside undisclosed upfront payments, and potential milestone and royalty payments.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, highlighted the potential of stem cell-based therapies, stating, “Stem cell-based cell therapy is a promising approach to modulate and scale cell therapies to ultimately provide tailor-made, off-the-shelf cell therapies at reasonable costs.”
Dr Joachim Fruebis, Corporate Vice President of Cell Therapy R&D at Novo Nordisk, added, “By integrating our strengths, we are setting the stage for significant breakthroughs to more efficiently advance our cell therapies.”
Overview of outsourcing trends 
